Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii

33Citations
Citations of this article
61Readers
Mendeley users who have this article in their library.

Abstract

Colistin and tigecycline are the only therapeutic options for extensively drug resistant Acinetobacter baumannii (XDR-AB), but there is little comparative study. This retrospective observation study evaluated two-colistin and tigecycline-antibiotics profiles like treatment success rate, negative conversion rate, the length of hospital stay, intensive care unit (ICU) stay and antibiotics use, mortality rate during hospital stay and adverse event rate, based on the medical record of XDR-AB positive patients who were treated at least 5 d with those intravenous antibiotics. Treatment success rate of colistin (n=39) and tigecycline (n=16) were not different: 48.7% and 43.8%, respectively (p=0.737), though negative conversion rate was significantly higher in the colistin group: 46.2% against 12.5% (p=0.049). There was no statistically significant difference in mortality rate between two groups during hospital stay (43.6% vs. 56.3%, p=0.393). There were no significant differences in the following parameters: the median length of hospital stay (46.0 d vs. 72.5 d), the median length of intensive care units stay (26.0 d vs. 27.0 d), the median length of antibiotics use (15.0 d vs. 13.0 d). The colistin group showed serum creatinine elevation (defined as elevation more than 2.0 mg/dL and 50% increase from the baseline) as 43.6% when compared with 12.5% of the tigecycline group (p=0.028). As a therapeutic option of XDR-AB, colistin showed significantly better negative conversion rate than tigecycline with more frequent nephrotoxic prevalence, and treatment success rate and mortality rate were not different from both antibiotics groups. © 2014 The Pharmaceutical Society of Japan.

References Powered by Scopus

Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections

1445Citations
N/AReaders
Get full text

Overview of nosocomial infections caused by gram-negative bacilli

1176Citations
N/AReaders
Get full text

Acinetobacter baumannii: Epidemiology, antimicrobial resistance, and treatment options

856Citations
N/AReaders
Get full text

Cited by Powered by Scopus

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)

552Citations
N/AReaders
Get full text

Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections

360Citations
N/AReaders
Get full text

Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review

151Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kwon, S. H., Ahn, H. L., Han, O. Y., & La, H. O. (2014). Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii. Biological and Pharmaceutical Bulletin, 37(3), 340–346. https://doi.org/10.1248/bpb.b13-00109

Readers over time

‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘240481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 22

67%

Researcher 8

24%

Professor / Associate Prof. 2

6%

Lecturer / Post doc 1

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 22

61%

Pharmacology, Toxicology and Pharmaceut... 9

25%

Agricultural and Biological Sciences 3

8%

Engineering 2

6%

Save time finding and organizing research with Mendeley

Sign up for free
0